These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 6979566)

  • 1. Effect of plicatic acid on human serum complement includes interference with C1 inhibitor function.
    Giclas PC
    J Immunol; 1982 Jul; 129(1):168-72. PubMed ID: 6979566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Control of C1 activation by nascent C3b and C4b: a mechanism of feedback inhibition.
    Ziccardi RJ
    J Immunol; 1986 May; 136(9):3378-83. PubMed ID: 3485688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
    Brown EJ; Ramsey J; Hammer CH; Frank MM
    J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-independent activation of C1. II. Evidence for two classes of nonimmune activators of the classical pathway of complement.
    Peitsch MC; Kovacsovics TJ; Tschopp J; Isliker H
    J Immunol; 1987 Mar; 138(6):1871-6. PubMed ID: 3029223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A mechanism for the spontaneous activation of the first component of complement, C1, and its regulation by C1-inhibitor.
    Bianchino AC; Poon PH; Schumaker VN
    J Immunol; 1988 Dec; 141(11):3930-6. PubMed ID: 3183385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unique C1 inhibitor dysfunction in a kindred without angioedema. I. A mutant C1 INH that inhibits C1-s but not C1-r.
    Wisnieski JJ; Knauss TC; Yike I; Dearborn DG; Narvy RL; Naff GB
    J Immunol; 1994 Mar; 152(6):3199-209. PubMed ID: 8144914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of first component of complement (C1) in guinea pig serum by a polysaccharide is prevented by C1 inhibitor.
    Schultz DR; Arnold PI
    J Immunol; 1981 Apr; 126(4):1558-61. PubMed ID: 7204976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of immune precipitation by purified classical pathway complement components.
    Naama JK; Hamilton AO; Yeung-Laiwah AC; Whaley K
    Clin Exp Immunol; 1984 Nov; 58(2):486-92. PubMed ID: 6333948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of C1 by soluble IgG aggregates as detected by a novel one-step hemolytic assay that specifically measures the proenzyme form of C1s.
    Doekes G; van Es LA; Daha MR
    J Immunol; 1983 Oct; 131(4):1924-9. PubMed ID: 6604753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C1- inactivator: its efficiency as a regulator of classical complement pathway activation by soluble IgG aggregates.
    Doekes G; van Es LA; Daha MR
    Immunology; 1983 Jun; 49(2):215-22. PubMed ID: 6852866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The functional inhibition of activated C1 inhibitor in normal human serum causes spontaneous consumption of the complement components C2, C3, C4, and factor B.
    Gronski P; Bodenbender L; Kanzy EJ; Piepenbrock M; Seiler FR
    Immunobiology; 1986 Apr; 171(3):252-62. PubMed ID: 3011651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of the classical pathway C3 convertase (EAC4b2a) by proteolytic enzymes.
    Loos M; Heinz HP
    Acta Pathol Microbiol Immunol Scand Suppl; 1984; 284():67-74. PubMed ID: 6375257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activation of complement by isolated human heart subcellular membranes.
    Giclas PC; Pinckard RN; Olson MS
    J Immunol; 1979 Jan; 122(1):146-51. PubMed ID: 762412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-independent C1 activation by E. coli.
    Tenner AJ; Ziccardi RJ; Cooper NR
    J Immunol; 1984 Aug; 133(2):886-91. PubMed ID: 6376630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of classical pathway components during alternative pathway--modulated immune complex aggregation: the role of C1 INH.
    Gronski P; Bodenbender L; Kanzy EJ; Seiler FR
    Behring Inst Mitt; 1984 Nov; (76):29-41. PubMed ID: 6335396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralization of vesicular stomatitis virus (VSV) by human complement requires a natural IgM antibody present in human serum.
    Beebe DP; Cooper NR
    J Immunol; 1981 Apr; 126(4):1562-8. PubMed ID: 6259260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional analysis of activated C1s, a subcomponent of the first component of human complement, by monoclonal antibodies.
    Matsumoto M; Nagaki K
    J Immunol; 1986 Nov; 137(9):2907-12. PubMed ID: 2428878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of immune precipitation by complement.
    Hong K; Takata Y; Sayama K; Kozono H; Takeda J; Nakano Y; Kinoshita T; Inoue K
    J Immunol; 1984 Sep; 133(3):1464-70. PubMed ID: 6747294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IgG and complement-mediated tissue damage in the absence of C2: evidence of a functionally active C2-bypass pathway in a guinea pig model.
    Wagner E; Platt JL; Howell DN; Marsh HC; Frank MM
    J Immunol; 1999 Sep; 163(6):3549-58. PubMed ID: 10477630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surface-bound capsular polysaccharide of type Ia group B Streptococcus mediates C1 binding and activation of the classic complement pathway.
    Levy NJ; Kasper DL
    J Immunol; 1986 Jun; 136(11):4157-62. PubMed ID: 3517165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.